Aehr Test Systems: Strong Prospects But Fully Valued

Revenues missed consensus and the company continues to burn cash, but a surge in system orders pushed AEHR's backlog to an all-time high. That backlog positions FY2027 for strong revenue growth, although the near-term sales mix is expected to be dominated by lower-margin package-level burn-in products. As a result, gross margins are unlikely to recover to prior levels in the near term.

Analysis

The recent spike in orders creates a classic optionality profile: a binary conversion path where FY2027 revenues can materially outpace current consensus if backlog converts on schedule, but the time distribution of shipments matters more than headline backlog size. If conversion skews to H2 FY2027, expect sequential revenue beats in late quarters and outsized quarter-to-quarter volatility; conversely, even a 20-30% slippage in conversion timing would push meaningful revenue recognition into FY2028 and keep market sentiment muted.

Margin dynamics are the principal offset to topline optionality. A persistent shift toward lower-margin package-level burn-in sales implies slower gross-margin recovery and structurally higher working capital needs as systems ramp, which in turn magnifies cash-burn sensitivity to build cadence. Practically, this means upside to EBITDA from revenue beats will be more muted than investors expect and that equity dilution or a financing event remains a realistic near-term tail risk if cash consumption stays elevated through the conversion period.

Second-order competitive and supply-chain effects favor vendors of consumables and thermal-cycle components while pressuring higher-end ATE vendors whose customers may defer expensive capital buys in favor of lower-cost package-level solutions. Monitor hyperscaler and AI-accelerator demand as the secular driver — if large cloud customers standardize on package-level burn-in, Aehr gains share and creates recurring consumable revenue; if they instead prefer integrated tester upgrades, Aehr’s backlog could be a short-lived tactical bump rather than a durable re-rating catalyst.

Key Decisions for Investors

• Buy a bullish calendar call spread on AEHR (buy 12–18 month LEAP call, sell near-dated 3–6 month call) to express upside from successful backlog conversion while funding part of the position; target >2x upside if FY2027 revenues beat guidance by 30–50%. Risk: theta on sold calls and total premium loss if backlog delays; hedge by size-limiting to 1–2% of book.
• Establish a short-dated hedge: buy 3–6 month OTM puts on AEHR sized to cover 20–30% of the long exposure to protect versus a dilution/qualification miss that could drop the stock 30–50% within months.
• Pair trade for sector-neutral alpha: long AEHR LEAP calls vs short a matched notional position in SMH (or a large ATE peer like TER) to isolate idiosyncratic upside from backlog conversion while hedging broader equipment-cycle risk; rebalance monthly on booking cadence updates.
• Event-driven alert: set buy triggers to add into any >20% post-earnings pullback provided management confirms >70% usable backlog conversion into firm shipment schedule and provides improved cash-flow cadence; if management signals continued high cash burn without a clear conversion timetable, reduce exposure immediately.